click below
click below
Normal Size Small Size show me how
Block IV drugs
PCL and lecture drugs
| Question | Answer |
|---|---|
| nafcillin class | penicillin-derived antibiotic |
| nafcillin MOA | inhibits 3rd and final stage of bacterial cell wall synthesis- they prevent the cross linkining of bacterial cell wall by binding to penicillin binding proteins (PBPs) causing bacterial cell lysis and death |
| ampicillin class | penicillin-derived antibiotic |
| ampicillin MOA | inhibits 3rd and final stage of bacterial cell wall synthesis- they prevent the cross linkining of bacterial cell wall by binding to penicillin binding proteins (PBPs) causing bacterial cell lysis and death |
| ceftriaxone sodium class | cephalosporin |
| ceftriaxone sodium MOA | inhibits 3rd and final stage of bacterial cell wall synthesis- they prevent the cross linkining of bacterial cell wall by binding to penicillin binding proteins (PBPs) causing bacterial cell lysis and death |
| gentamicin class | aminoglycoside |
| gentamicin MOA | interferes with bacterial protein synthesis by binding to 30S ribosomal subunit |
| edrophonium chloride class | short acting cholinesterase inhibitor |
| edrophonium chloride MOA | competes with ACh for it's binding site on AChE, interfering with ACh enzymatic destruction, potentiating the action of ACh on it's receptors |
| pyridostigmine class | intermediate acting cholinesterase inhibitor |
| pyridostigmine MOA | competes with ACh for it's binding site on AChE, interfering with ACh enzymatic destruction, potentiating the action of ACh on it's receptors |
| azathioprine class | immunosuppressive |
| azathioprine MOA | suppresses hypersensitivities of the cell-mediated type and causes variable alterations in Ab production |
| prednisone, methylprednisone | corticosteriods |
| prednisone, methylprednisone MOA | binds to the cytoplasmic cortisol receptor; the hormone-receptor complex enters the nucleus and acts as a TF to alter gene transciption; also inhibits phospholipase A2 to have anti-inflammatory effects |
| mycophenolate mofetil class | immunosuppressive |
| mycophenolate mofetil MOA | inhibitor of inosine monophosphate dehydrogenase (IMPDH), which inhibits the de novo synthesis of guanosine nucleotides; has cytostatic effects on lymphocytes |
| carbamzepine class | neurologic agent and TCA |
| carbamzepine MOA | inhibit serotonin and NE uptake, modulate Na+ and K+ channels, block NDMA (glutamate R) and adenosine receptors, and inhibit TNF-alpha |
| amitriptyline class | TCA |
| amitripyline MOA | potentiates the actions of NE and serotonin by blocking their uptake by transporter on the presynaptic membrane; stimulates 5-HT descending pathways |
| propoxyphene class | opiod analgesic |
| propoxyphene MOA | weak opioid agonist, binding primarily to mu opiod receptors, producing analgesia and other CNS effects |
| buspirone class | anxiolytic |
| buspirone MOA | partial 5-HT1A receptor agonist |
| alprazolam class | anxiolytic, sedative, hypnotic |
| alprazolam MOA | facilitates GABA-mediated inhibition of neuronal activity in the CNS |
| sertraline class | SSRI antidepressant |
| sertraline MOA | inhibition of serotonin uptake at the neuronal membrane |
| gabapentin class | anticonvulsant- neurologic agent |
| gabapentin MOA | GABA analog; interacts with cortical neurons at auxillary subunits of voltage-gated Ca++ channels |
| tramadol class | analgesic |
| tramadol MOA | central opiate receptor agonist; inhibits NE and serotonin reuptake in the CNS |
| duloxetine class | antidepressant |
| duloxetine MOA | inhibits the reuptake of NE and serotonin |
| pregabalin class | Ca++ channel blocker; analgesic, neurologic agent |
| pregabalin MOA | GABA analog; binds to the alpha-2-delta subunit of voltage-gated Ca++ channels in the CNS to reduce neuronal Ca++ currents to reduce pain |
| metoclopramide class | prokinetic agent, antiemetic |
| metoclopramide MOA | 5-HT4 agonist; D2 antagonist |
| tegaserod maleate class | prokinetic agent |
| tegaserod maleate MOA | selective 5-HT4 partial agonist |
| Beta-1a interferon class | biologic response agent, neurologic agent |
| Beta-1a interferon MOA | increases the levels of 2,5-oligo-adenylate synthetase, which degrades viral RNA |
| Baclofen class | skeletal muscle relaxant |
| baclofen MOA | GABA-B agonist: depresses output from the spinal cord |
| mitoxantrone class | anti-neoplastic agent |
| mitoxantrone MOA | inhibits DNA and RNA synthesis and topoisomerase II to have cytocidal effects |
| rituximab class | anti-neoplastic agent, biologic response modifier |
| rituximab MOA | monoclonal Ab that binds to the CD20; causes cell lysis and inhibits Ab release |
| fluconazole class | antifungal |
| fluconazole MOA | inhibits fungal cytochrome P-450 C-14 alpha demethylation, resulting in disruption of packing of acyl chains of phospholipids and inhibiting fungal growth |
| acyclovir class | antiviral |
| acyclovir MOA | as acyclovir triphosphate, it stops replication of viral DNA in 3 ways |
| doxycycline class | tetracycline antibiotic |
| doxycycline MOA | binds to the 30S ribosomal subunit, preventing protein translation |
| carbidopa-levodopa class | antiparkinsonian agent |
| carbidopa-levodopa MOA | Levodopa: converted to dopamine; C: inhibits DOPA decarboxylase in periphery |
| pramipexole class | antiparkinsonian agent; dopaminergic |
| pramipexole MOA | dopamine receptor agonist |
| enalapril maleate class | ACE inhibitor |
| enalapril maleate MOA | by inhibition of angiotensin converting enzyme, it stops the conversion of angiotensin I to angiotensin II, decreasing vasopressor activity and aldosterone secretion |
| selegiline class | antiparkinsonian agent, MAOI |
| selegiline MOA | Antagonist of MAO-B, the main MAO in the brain, which metabolizes dopamine. It may also block presynaptic dopamine uptake and decreases free radical production |
| prazosin class | sympatholytic and antihypertensive agent |
| prazosin MOA | Selective alpha-1 antagonist |
| ASA class | analgesic, platelet inhibitor, anti-inflammatory agent |
| ASA MOA | irreversibly inhibits COX via acetylation of ser residues and the production of thromboxanes and prostaglandins |
| ibuprofen, sulindac, ketolorac class | NSAID |
| ibuprofen (reversible), sulindac (pro-drug), ketolorac MOA | NSAIDs: competitively inhibit both COX-1 and COX-2, decreasing PG synthesis. Is anti-inflam, anti-platelet, and anti-pyretic. Actions primarily peripheral- CNS involvement only in overdose (tinnitus, MA, thirst). |
| celecoxib, rofecoxib, valdecoxib class | NSAID |
| celcoxib, rofecoxib, valdecoxib MOA | more selectively inhibits COX-2 to have anti-inflammatory, analgesic, and anti-pyretic effects |
| acetaminophen class | non-opioid analgesic |
| acetaminophen MOA | Works in the CNS to increase pain threshold and reduce fever Does NOT inhibit COX and is NOT anti-inflammatory |
| morphine, hydromorphine, meperidine, fentanyl, methadone, codeine, hydrocodone, propoxyphene MOA | full opiate agonists; cause hyperpolarization, inhibition of cell firing, presynaptic inhibition of NT release, and may cause excitation by dysinhibition. Inhibit adenylate cyclase, decreasing cAMP and also activate MAPKs and PLC |
| pentazocine, nalbuphine, butorphanol MOA | mixed opiate agonists/antagonists; block delta, kappa, and mu receptors, but still have some analgesic effects following opiate MOA |
| naloxone, naltrexone MOA | opioid receptor antagonists; bind to and block the actions of opiates at mu and delta opioid receptors |
| dextromethorphan, levopropoxyphene MOA | centrally active antitussive agents. Dextromorphan can block NDMA receptors and reverse tolerance to opioids. |
| phenylephrine class | selective alpha 1 receptor agonist |
| prazosin, terazosin, doxazosin, tamsulosin class | selective alpha 1 antagonist |
| clonidine, dexmedetomidine class | alpha-2 receptor agonist |
| yohimbine, atipamezole class | selective alpha 2 antagonist |
| dobutamine class | B-1 receptor agonist |
| metoprolol, atenolol class | B-1 receptor antagonist |
| terbutaline, albuterol class | B-2 agonist |
| direct acting sympathomimetics action | act on adrenergic receptors |
| indirect-acting sympathomimetic actions | enhance catecholamine levels at the receptor |
| amphetamine class | indirect acting sympathomimetic |
| amphetamine MOA | enhances catecholamine levels at receptors; releases NE in the absence of an AP by entering the nerve terminal via uptake 1 |
| ephendrine class | direct acting sympathomimetic |
| ephendrine MOA | synthetic analog of Epi and NE, directly activating the receptors of these catecholamines |
| bromocreptine MOA | postsynaptic dopamine receptor agonist; used after activity of DOPA decarboxylase is reduced |
| amantadine MOA | inhibits the penetration of A2 influenza virus into cells. In PD, may inhibit the uptake of dopamine intor synaptosomes and may cause dopamine release because it has an indirect amphetamine-like effect |
| trihexyphenidyl, benztropine MOA | anticholinergic: inhibit cholinergic receptors to decrease cholinergic hyperactivity |
| ropinirole MOA | non-ergoline dopamine receptor agonist |
| cabergoline MOA | ergoline structure D-2 receptor agonist |
| tolcapone, entacapone MOA | COMT inhibitors; inhibit COMT synthesis of 3-O-methyl-dopa, prolonging the plasma half life of L-dopa |
| clopidogrel class | platelet inhibitor |
| clopidogrel MOA | selectively and irreversibly inhibits ADP induced platelet aggregation and subsequently prevents the binding of fibrinogen to platelets, preventing platelet aggregation |
| atorvastatin class | HMG-CoA reductase inhibitor |
| atorvastatin MOA | selective and competitive inhibitor of the rate-limiting enzyme in the cholesterol synthesis pathway |
| phenytoin sodium class | anti-convulsant |
| phenytoin sodium MOA | limits the spread of seizure activity and seizure propagation by slowing rate of recovery of Na+ channels from inactivation, thereby decreasing neuron excitability |
| aspirin MOA | salicylate; COX inhibitor |
| carbamazapine class | anti-convulsant |
| carbamazapine MOA | blocks voltage-gated Na+ channels, inhibiting sustained repetitive firing |
| doxazosin class | alpha blocker; sympatholytic |
| doxazosin MOA | Competitively inhibits alpha-1 adrenergic receptors in the sympathetic nervous system leading to peripheral vasodilation, decreased peripheral vascular resistance, and lowered blood pressure |
| Rivastigmine class | cholinesterase inhibitor |
| Rivastigmine MOA | Selective inhibitor of brain ACh-esterase. Preferential inhibition of G-1 isoforms of ACh-esterase (higher concentrations in the hippocampus and cortex). "Pseudo-irreversible" actions due to its long binding time and short dissociation from ACh-esterase |
| endogenous opioids | pro-opiomelanocortin (POMC), enkephalins, dynorphans |